Modality
siRNA
MOA
GLP-1ag
Target
IL-13
Pathway
T-cell
NASHPompeET
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
~Feb 2020
→ ~May 2021
Phase 2
Aug 2021
→ Feb 2027
Phase 2Current
NCT03635868
1,171 pts·NASH
2025-05→2027-02·Terminated
NCT06192622
1,157 pts·NASH
2021-08→2026-10·Not yet recruiting
2,328 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-136mo awayPh2 Data· NASH
2027-02-0310mo awayPh2 Data· NASH
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P2
Not yet…
P2
Termina…
Catalysts
Ph2 Data
2026-10-13 · 6mo away
NASH
Ph2 Data
2027-02-03 · 10mo away
NASH
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03635868 | Phase 2 | NASH | Terminated | 1171 | DAS28 |
| NCT06192622 | Phase 2 | NASH | Not yet recr... | 1157 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR | |
| Elrarapivir | Iovance | Phase 2 | IL-13 |